Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M407190200 on September 1, 2004

J. Biol. Chem., Vol. 279, Issue 46, 48434-48442, November 12, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/46/48434    most recent
M407190200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, D.
Right arrow Articles by Hawiger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, D.
Right arrow Articles by Hawiger, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Nuclear Import of Proinflammatory Transcription Factors Is Required for Massive Liver Apoptosis Induced by Bacterial Lipopolysaccharide*

Danya Liu{ddagger}, Chunsheng Li{ddagger}, Yiliu Chen{ddagger}, Christie Burnett{ddagger}, Xue Yan Liu{ddagger}, Sheila Downs{ddagger}, Robert D. Collins§, and Jacek Hawiger{ddagger}

From the {ddagger}Departments of Microbiology and Immunology and §Pathology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232

Received for publication, June 28, 2004 , and in revised form, August 24, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Stimulation of macrophages with lipopolysaccharide (LPS) leads to the production of cytokines that elicit massive liver apoptosis. We investigated the in vivo role of stress-responsive transcription factors (SRTFs) in this process focusing on the precipitating events that are sensitive to a cell-permeant peptide inhibitor of SRTF nuclear import (cSN50). In the absence of cSN50, mice challenged with LPS displayed very early bursts of inflammatory cytokines/chemokines, tumor necrosis factor {alpha} (1 h), interleukin 6 (2 h), interleukin 1 {beta} (2 h), and monocyte chemoattractant protein 1 (2 h). Activation of both initiator caspases 8 and 9 and effector caspase 3 was noted 4 h later when full-blown DNA fragmentation and chromatin condensation were first observed (6 h). At this time an increase of pro-apoptotic Bax gene expression was observed. It was preceded by a decrease of anti-apoptotic Bcl2 and BclXL gene transcripts. Massive apoptosis was accompanied by microvascular injury manifested by hemorrhagic necrosis and a precipitous drop in blood platelets observed at 6 h. An increase in fibrinogen/fibrin degradation products and a rise in plasminogen activator inhibitor 1 occurred between 4 and 6 h. Inhibition of SRTFs nuclear import with the cSN50 peptide abrogated all these changes and increased survival from 7 to 71%. Thus, the nuclear import of SRTFs induced by LPS is a prerequisite for activation of the genetic program that governs cytokines/chemokines production, liver apoptosis, microvascular injury, and death. These results should facilitate the rational design of drugs that protect the liver from inflammation-driven apoptosis.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Programmed cell death (apoptosis) is the major mechanism of embryonic development and remodeling of tissues and organs, homeostatic control of immune cells that recognize self and non-self antigens, and removal of virally infected cells (1). Apoptosis of hepatocytes may occur in fulminant hepatitis, an inflammatory process that is caused by viral and non-viral agents (2). For example, recent gene therapy approaches to correct an inborn error of metabolism led to fulminant liver failure (3). This inflammation-related complication of gene therapy impedes broader application of viral vectors (4, 5). The sequence of intracellular signaling events that underlie inflammation-driven development of ultimately fatal liver apoptosis remains incompletely understood.

Fulminant liver apoptosis has been studied in several animal models. These studies indicate that activation of T cells with concanavalin A (6) or with agonists that interact with T cell receptor such as staphylococcal enterotoxin B can lead to massive apoptosis (7, 8). Staphylococcal enterotoxin B-induced apoptosis occurs under conditions of metabolic stress imposed by 2-amino-2-deoxy-D-galactosamine (D-Gal).1 Similarly, activation of macrophages with their Toll-like receptors (TLR) agonists, such as lipopolysaccharide (LPS, endotoxin), induces massive liver apoptosis when animals are treated with ethanol or D-Gal (9, 10). By reversibly depleting hepatic stores of uri-dine triphosphate (UTP), D-Gal sensitizes hepatocytes to the cytotoxic effects of tumor necrosis factor {alpha} (TNF{alpha}) (10, 11). Accordingly, massive liver apoptosis induced by a macrophage agonist, LPS, or a T cell agonist, staphylococcal enterotoxin B, in combination with a metabolic inhibitor, D-Gal, was abrogated in animals deficient in TNF{alpha} receptor 1 (TNFR-1) (12–14). These in vivo models of liver apoptosis offer an excellent way to study fulminant liver injury mediated by inflammatory cytokines because they provide a well defined and reliable end point, which is relevant to human disease states.

The genetic programs for inflammation and apoptosis are regulated by stress-responsive transcription factors (SRTFs) either alone or in various combinations (15). These SRTFs include nuclear factor {kappa}B (NF{kappa}B), nuclear factor of activated T cells, activator protein 1, and signal transducer and activator of transcription 1. In response to proinflammatory stimuli, SRTFs are translocated to the nucleus via a set of adaptor proteins known as importins/karyopherins {alpha}, which in tandem with their {beta} subunit ferry the cargo to the nucleus (15, 16). Importin/karyopherin {alpha}2 (Rch1, KPNA2) is the target for a cell-permeant peptide-cyclized form of SN50 (cSN50), which prevents the nuclear import of SRTFs (17, 18). Here we report in vivo studies with cSN50 showing that this cell permeant peptide prevents liver apoptosis and death in a murine model of LPS toxicity. These findings demonstrate a key role for SRTFs in the development of fulminant liver injury induced by LPS and mediated by inflammatory cytokines and chemokines.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Peptide Synthesis and Purification—cSN50 and SM were synthesized, purified, filter-sterilized, and analyzed as described elsewhere (7, 18).

Maintenance and Treatment of Cell Line—Murine macrophage cell line RAW 264.7 (RAW) was obtained from the American Type Culture Collection (Manassas, VA; TIB-71). These cells were cultured in Dulbecco's modified Eagle's medium (Cellgro, VA) supplemented with 10% heat-inactivated fetal bovine serum containing no detectable LPS (<0.006 ng/ml as determined by the manufacturer, Atlanta Biological, Norcross, GA), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. The viability of RAW cells was >80% in all experiments. RAW cells were placed in 96-well plates (200 µl/well at 2 x 106/ml) and treated with different concentrations of cSN50 and SM peptides (0, 5, 10, 30, and 50 µM) 30 min before stimulation by 2 ng/ml LPS from Escherichia coli 0127:B8 (Sigma). Each experimental sample was run in duplicate or triplicate. Cells were incubated for 6 h at 37 °C in 5% CO2. Supernatant samples from the medium of RAW cells treated with LPS and/or peptide were collected and frozen at -80 °C until assayed for cytokine levels.

Animal Treatment Protocols—Female C57BL/6 mice (8–12 weeks old, ~20 g) were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were injected intraperitoneally with 1 µg of LPS (5 µg/ml, Sigma) and 20 mg of D-Gal (100 mg/ml, Sigma), both in pyrogen-free saline. Mice were randomly divided into two groups; diluent control, which received 5% dimethyl sulfoxide in sterile H2O, or a treatment group that received the cSN50 peptide (0.7 mg in 200 µl of 5% dimethyl sulfoxide in sterile H2O as diluent). The treatment group received seven intraperitoneal injections before (30 min) and after (30, 90, 150, and 210 min and 6 and 12 h) LPS and D-Gal challenge. However, the control group usually received five intraperitoneal injections of diluent because of the worsening condition of the animals and their rapid death. An additional group of 15 mice received the SM peptide (cell-permeant but functionally inactive analog of cSN50) in a dose of 2 mg given intraperitoneally before (30 min) and after (30, 90, 150, and 210 min). Due to the rapid demise of these mice, two additional injections at 6 and 12 h could not be administered. Animals were observed at hourly intervals for signs of acute toxicity (piloerection, ataxia, and the lack of reaction to cage motion) that herald imminent death. Inactive animals were euthanized. Animals without apparent signs of disease (survivors) were euthanized at 72 h after LPS and D-Gal. Some survivors were observed for an additional 7 days and then were euthanized. The blood samples from the saphenous vein were collected in heparinized tubes for plasma separation and in regular tubes for serum separation before and after LPS and D-Gal challenge at the indicated times. Some experimental animals were sacrificed at 2, 4, and 6 h for collection of organs. The liver was removed, and some pieces were frozen in liquid nitrogen and stored at -80 °C for caspase assay and RNA isolation. Other parts of the liver as well as other organs (spleen, kidney, lung, and heart) were immersed in 10% formalin for histologic analysis. Animal handling and experimental procedures were performed in accordance with the American Association of Accreditation of Laboratory Animal Care guidelines and approved by the Institutional Animal Care and Use Committee.

Cytokine Assays of Plasma and Cultured Cell Supernatants— Supernatant levels of TNF{alpha}, interleukin (IL)-1{beta}, and IL-6 in cultured RAW cells and plasma levels of IL-1{beta} were measured by enzyme-linked immunosorbent assay according to the manufacturer's instructions (ELISA, R&D Systems, Minneapolis, MN). TNF{alpha} and IL-6 in plasma, monocyte chemoattractant protein 1 (MCP-1) in plasma, and in cultured RAW cell supernatant were measured by a Cytometric Bead Array (BD Biosciences) according to the manufacturer's instructions (7, 19).

Measurement of Liver Enzymes—Activities of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in serum according to the modified manufacturer's instructions (Catachem Inc., Bridgeport, CT). Briefly, ALT or AST-working reagent and serum samples on ice were mixed at 12:1 ratio in cuvettes and then incubated in a 37 °C water bath for 5 min. After incubation, the decrease in absorbance at 340 nm was monitored at 1-min intervals for at least 5 min, and the decrease in absorbance per minute was calculated ({Delta}A). ALT or AST concentration (unit/liter) in samples was calculated using the formula, unit/liter = {Delta}A x 1929.

Caspase Assays—Caspase 3, 8, and 9 activities in liver tissue were measured using a Caspase-Glo assay kit (Promega) and modified protocol. Briefly, the proluminescent substrate containing the DEVD, LETD, or LEHD (sequences are in a single-letter amino acid code) is cleaved by caspase-3, caspase-8, and caspase-9, respectively. After caspase cleavage, a substrate for luciferase (aminoluciferin) is released; this results in the luciferase reaction and the production of luminescent signal. Cytosolic extracts from liver tissue were prepared by Dounce homogenization in hypotonic extraction buffer (25 mM HEPES, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 1 mM Pefablock, and 1 µg/ml each pepstatin, leupeptin, and aprotinin) and subsequently centrifuged (15 min, 13,000 rpm, 4 °C) (19). The protein concentration of supernatant was adjusted to 1 mg/ml with extraction buffer and stored at -80 °C. An equal volume of reagents and 10 µg/ml cytosolic protein were added to a white-walled 96-well plate and incubated at room temperature for 1 h. The luminescence of each sample was measured in a plate-reading luminometer.

RNA Preparation and cDNA Synthesis—Total RNA was extracted from frozen liver tissue with Versagene RNA tissue kit (Gentra Systems, Inc., Minneapolis, MN) and treated with DNase (Versagene DNase treatment kit, Gentra Systems, Inc.) following the manufacturer's instructions. The integrity of RNA preparations was assessed using a NanoDrop® ND-1000 spectrophotometer and agarose gel electro-phoresis. First-strand cDNA was synthesized with a High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). Briefly, 1 µg of total RNA was used as the template for synthesis of cDNA in a 50-µl reaction and incubated at 25 °C for 10 min followed by 37 °C for 120 min.

RNA Quantification with Specific Probes by Real-time PCR—Detection of mRNA expression levels by real-time PCR with a reporter probe has been established in amplification kinetics studies using reverse-transcribed transcripts as template (20, 21). RNA quantification of specific genes was performed using a TaqMan assay (Applied Biosystems). A probe for eukaryotic 18 S rRNA endogenous control (product 4319413E) was VIC/minor groove binder-labeled. The primers and FAM/minor groove binder-labeled probes for the following genes were purchased from ABI (TaqMan Assay-on-Demand): Bcl2 (assay ID Mm00477631_m1), BclXL (assay ID Mm00437783_m1), and Bax (assay ID Mm00432050_m1). Eukaryotic 18 S rRNA was used as an endogenous control in a multiplex PCR reaction with a primer/probe of the gene of interest. For each reaction, 2x TaqMan universal PCR master mix (Applied Biosystems), 900 nM primers, and 250 nM probes in 10 µl were added to 384-well plate. Real-time PCR and subsequent analysis were performed with the ABI Prism 7900HT sequence detection system (SDS v2.1) (Applied Biosystems) using the following conditions: 50 °C for 2 min, 95 °C for 10 min, and then 40 cycles of amplification (95 °C denaturation for 15 s, 60 °C annealing/extension for 1 min). All PCR reactions were performed in triplicate for each sample and were repeated three times.

Platelet Count, Detection of Fibrin Degradation Products (FDPs), and Plasminogen Activator Inhibitor 1 (PAI-1) Total Antigen—Heparinized fresh blood was diluted 1:60 in 1% ammonium oxalate (EM Science) and rocked for 20 min. The sample was added to hemacytometer, and after 20 min, platelets were counted. FDPs in serum were detected by staphylococcal clumping test as described elsewhere (22). Briefly, staphylococci (Staphylococcus aureus sp. aureus ATCC 25904) that express clumping factor were grown and processed to prepare a standardized smooth bacterial suspension for determining a clumping titer in serum samples. The clumping titer was expressed as a reciprocal of the highest dilution of tested serum giving a positive clumping reaction. PAI-1 total antigen in plasma was measured by an ELISA kit according to the manufacturer's instructions (Molecular Innovations, Inc., Southfield, MI).

Histology Analyses—Organ samples (liver, spleen, kidney, lung, and heart) were collected from mice showing typical signs of acute toxicity shortly before death or from surviving mice that were euthanized after 72 h or at the indicated times. Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin or periodic acid-Schiff and hematoxylin to assess injury and hemorrhage. Apoptosis of the liver was evaluated by characteristic cytologic changes and by TdT-dependent dUTP-biotin nick end-labeling (TUNEL) assay using the Apop Tag reagent (Intergen) according to the manufacturer's instructions.

Statistical Analysis—All experimental data except survival were expressed as the mean ± S.E. A one-way analysis of variance, a two-way repeated measure analysis of variance, and Student's t test were used to determine the significance of the difference. A log rank test was used for analysis of survival.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
In Vivo System for Studying Apoptosis in the Liver—Mice challenged with a high dose of LPS (40 mg/kg) do not manifest hepatocyte apoptosis despite excessive production of TNF{alpha} (18). This tolerance of hepatocytes to TNF{alpha} can be dramatically lowered by administering LPS (50 µg/kg) in combination with D-Gal (10, 23, 24), which leads to massive liver apoptosis. This striking shift in LPS toxicity led us to explore the mechanism of LPS action on the apoptotic process in sensitized mice. As shown in Fig. 1A, sequential analysis of liver apoptosis, manifest by DNA fragmentation detected by TUNEL assay and chromatin condensation, indicates the lack of major changes until 4 to 6 h after the administration of LPS and D-Gal. Concomitant with massive apoptosis, the livers displayed hemorrhagic necrosis at 6 h, an apparent consequence of a break-down of endothelial integrity. This form of microvascular injury is presumably responsible for platelet thrombi as shown in Fig. 1B. Thus, the development of massive apoptosis of the liver is accompanied by hemorrhagic necrosis, a consequence of microvascular injury. The lack of DNA fragmentation and a paucity of other detectable changes in liver architecture during the first 4 h raise a series of questions about the dynamics of liver apoptosis induced by LPS. First, is this process regulated by nuclear import of SRTFs? Second, would blockade of nuclear import result in (a) cytoprotection against the leakage of liver enzymes, (b) suppression of initiator and effector caspases, (c) maintenance of the balance between the expression of anti-apoptotic and pro-apoptotic genes, and (d) prevention of hemorrhagic necrosis? To address these mechanistic questions, we performed time course studies and monitored markers of inflammation, hepatocyte dysfunction, apoptosis, and microvascular injury.



View larger version (77K):
[in this window]
[in a new window]
  		FIG. 1.
Time-dependent development of liver apoptosis and hemorrhagic necrosis. A, liver sections from C57BL/6 mice injected with LPS and D-Gal and sacrificed at indicated times were stained with hematoxylin and eosin (H & E) or with Apop Tag (TUNEL assay). A single dying cell is seen at 4 h (arrow), whereas there is massive necrosis, hemorrhage, and apoptosis at 6 h. B, liver section at 6 h stained with hematoxylin and eosin shows aggregates of platelets within a blood vessel (arrow).

 
LPS-induced Expression of Inflammatory Cytokines and Chemokines in Murine Macrophages Depends on Nuclear Import of SRTFs—Macrophages comprise an estimated 20–40% of the liver cells in rats and mice and display TLR4, a receptor for LPS (23, 25, 26). In response to TLR4-generated signals, NF{kappa}B and other SRTFs are deployed to the nucleus, where they regulate a myriad of genes encoding mediators of inflammation and apoptosis (15). A cell-permeant nuclear import inhibitor, cSN50 peptide, was developed by us to suppress the deployment of SRTFs in the nucleus (18). This bipartite inhibitor contains a membrane-translocating motif, which allows rapid penetration of cell membrane, and a "cargo" comprised of a cyclized nuclear localization sequence (NLS) that enables this peptide to competitively inhibit cytoplasmic/nuclear import of NLS-containing SRTFs. To validate the dependence of LPS-induced inflammatory cytokines/chemokines production on nuclear import of SRTFs, we evaluated the potency of cSN50 peptide as compared with its mutated analog, SM peptide, in cultured murine macrophage RAW cells stimulated with LPS. As shown in Fig. 2, the cSN50 peptide in a range of concentrations from 5 to 50 µM significantly inhibited LPS-induced expression of inflammatory cytokines TNF{alpha} (p < 0.0001), IL-6 (p < 0.0001), IL-1{beta} (p < 0.0001), and chemokine MCP-1 (p < 0.0001). In contrast, the cell-permeant SM peptide that contains mutated NLS as cargo was without effect on LPS-induced inflammatory cytokine/chemokine expression, attesting to the specificity of a nuclear import inhibitory sequence. Importantly, these two peptides, cSN50 and SM, did not affect the viability of LPS-stimulated RAW macrophages (>80% under these experimental conditions). These results extend our previous findings of inhibition of SRTF nuclear import in LPS-stimulated macrophages (18) to the concentration-dependent inhibition of inflammatory cytokine/chemokine expression.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 2.
Nuclear import inhibitor, the cSN50 peptide, suppresses in a concentration-dependent manner inflammatory cytokine and chemokine expression in murine macrophage RAW cells induced by LPS. cSN50 peptide (triangles) and mutant peptide SM (circles) were added to cells at different concentrations 30 min before the addition of LPS (2 ng/ml). Supernatant samples from the medium were collected after 6 h of culture and analyzed by ELISA for levels of cytokines TNF{alpha} (A), IL-6 (B), and IL-1{beta} (C) or by Cytometric Bead Array for chemokine MCP-1 (D). Error bars in panels A–D indicate the ± S.E. of the mean value from three independent experiments. p values represent the significance of difference between the SM peptide and cSN50 peptide-treated groups (two-way ANOVA) as well as the cytokine level with or without cSN50 peptide (one-way ANOVA).

 
Time Course of Inflammatory Cytokines and Chemokine Expression—We serially monitored the levels of inflammatory cytokines/chemokines in blood to investigate the sequence of events preceding massive apoptosis of the liver, which was not fully apparent until 6 h after administration of LPS and D-Gal (Fig. 1). As shown in Fig. 3, TNF{alpha} levels rose very rapidly in the circulation, reaching a peak in plasma at 1 h. Bursts of IL-6 and chemokine MCP-1 at 2 h followed a very early rise in TNF{alpha}. On the other hand IL-1{beta} showed a more progressive rise in systemic levels. Administration of LPS alone induced similar response of inflammatory cytokines and chemokine, but D-Gal alone did not have a detectable effect on inflammatory cytokines and chemokine production in vivo (data not shown), thereby confirming the requirement for LPS to induce an inflammatory cytokine/chemokine response. This response was suppressed significantly by the cSN50 peptide, affirming the dependence of the in vivo production of inflammatory mediators on the nuclear import of SRTFs.



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 3.
Time-dependent expression of inflammatory cytokines and a chemokine in control and cSN50 peptide-treated mice. Wild-type C57BL/6 mice were treated with cSN50 peptide (0.7 mg in 200 µl of 5% dimethyl sulfoxide) or diluent (200 µl) in 7 intraperitoneal injections before (30 min) and after (30, 90, 150, and 210 min and 6 and 12 h) intraperitoneal administration of LPS with D-Gal. Blood plasma levels of cytokines TNF{alpha} (A), IL-6 (B), IL-1{beta} (C), and chemokine MCP-1 (D) were measured in diluent controls (circles) and cSN50 peptide-treated animals (triangles) over the 6-h time period after LPS/D-Gal challenge. Error bars in panels A–D indicate the ± S.E. of the mean value in five mice that are represented by each data point. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups (two-way ANOVA).

 
Time-dependent Induction of Enzyme Markers for Hepatocyte Injury—ALT and AST measured in serum provide an index of hepatocyte integrity. Leakage of ALT/AST into the extracellular compartment and a subsequent rise in serum reflect hepatocyte damage. These enzymes are significantly elevated in a number of conditions that cause liver injury including viral and bacterial infections, alcohol, and drug toxicity (27). As shown in Fig. 4, the serum ALT and AST activity increased rapidly during the first 4 h after administration of LPS and D-Gal and then dropped precipitously at 6 h. This drop most likely reflects liver failure (see Fig. 1). Significantly, the cSN50 peptide prevented the rise in liver enzymes ALT and AST. Thus, by suppressing expression of inflammatory mediators, a nuclear import inhibitor exerts a cytoprotective effect on liver cells in this model. Solo administration of LPS or D-Gal to the control groups of mice produced a moderate increase in serum ALT and AST levels with delayed peaks of activity at 8 and 24 h, respectively, and without massive apoptosis or reduced survival (data not shown).



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 4.
Time-dependent liver enzyme induction by LPS and D-Gal in control and cSN50 peptide-treated mice. Wild-type C57BL/6 mice were treated with cSN50 peptide (0.7 mg) or diluent as indicated in Fig. 3 before and after intraperitoneal administration of LPS with D-Gal. Blood serum levels of ALT (A) and AST (B) were measured in diluent controls (circles) and cSN50 peptide-treated animals (triangles) over the 6-h time period after LPS/D-Gal challenge. Error bars indicate the ± S.E. of the mean value in five mice that are represented by each data point. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups (two-way ANOVA). U/L, unit/liter.

 
Activation Kinetics of Initiator and Effector Caspases—Although the peak of TNF{alpha} required for activation of its cognate death receptor TNFR-1 occurs at 1 h, activation of initiator and effector caspases is observed much later. This family of intracellular aspartate-specific cysteine proteases exists as inactive proenzymes ("zymogens"). Caspase activation can be measured using specific substrates. Caspase 8 mediates TNFR-1-proximal events in cell death signaling. Caspase 9 is activated by cytochrome c released from mitochondria. Caspase 3 is dubbed DEVDase because it cleaves a DXXD motif, a substrate shared with caspase 7; it is an "executioner caspase," which can be activated directly by caspase 8 or by caspase 9 (28–32). Thus, a cascade of proteolytic events initiated by TNF{alpha} and mediated by caspases leads to nucleosomal DNA fragmentation and chromatin condensation as documented in Fig. 1. Despite a very early burst in TNF{alpha} production (see Fig. 3), the caspase cascade was considerably delayed. As shown in Fig. 5, the initiator caspases 8 and 9 were activated between 4 to 6 h in mice given LPS and D-Gal. Consistent with these findings, "effector" caspase 3 was not activated during the first 4 h. Caspase 3 (and caspase 7) showed a burst of proteolytic activity at 6 h. Thus, anti-apoptotic mechanisms significantly slowed death receptor signaling initiated by TNF{alpha}. Moreover, caspase activation was almost totally suppressed in the livers of mice treated with the cSN50 peptide. Thus, nuclear import of SRTFs is a rate-limiting step for initiation of pro-apoptotic signaling by TNF{alpha} and other inflammatory cytokines in the LPS-induced model of liver apoptosis (10, 11, 24).



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 5.
Time-dependent activation of initiator and effector caspases in control and cSN50 peptide-treated mice. Wild-type C57BL/6 mice were treated with cSN50 peptide (0.7 mg in 200 µl of 5% dimethyl sulfoxide) or diluent before and after intraperitoneal administration of LPS with D-Gal according to the protocol described under "Experimental Procedures." Caspase activities in liver were measured in diluent controls (open bar) and cSN50 peptide-treated animals (solid bar). Error bars indicate the ± S.E. of the mean value in four mice that are represented by each data point. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups (two-way ANOVA). RLU, relative light units.

 
Alteration in the Balance between Gene Expression of Anti-apoptotic and Pro-apoptotic Proteins Induced by LPS and D-Gal—The observed delay in caspase activation could be due to the initial balance between anti-apoptotic Bcl2 family proteins e.g. Bcl2, BclXL, and pro-apoptotic proteins, e.g. Bax, Bid. Such a balance is important for maintaining cell homeostasis (33, 34). Quantitative analysis of the liver transcripts of the pro-apoptotic gene bax indicated that its expression was significantly increased at 6 h after challenge with LPS and D-Gal (Fig. 6A). Conversely, expression of Bcl2 and BclXL was significantly decreased at 2 h (Fig. 6, B and C). Treatment with the cSN50 peptide suppressed the transcriptional activation of Bax gene and prevented the subsequent shift in balance of these transcripts that favors apoptosis.



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 6.
Gene expression of pro-apoptotic (Bax) and anti-apoptotic (Bcl2 and BclXL) members of the Bcl2 family in the livers of control and cSN50 peptide treated mice. Wild-type C57BL/6 mice were treated with cSN50 peptide (0.7 mg in 200 µl of 5% dimethyl sulfoxide) or diluent before and after intraperitoneal administration of LPS with D-Gal according to the protocol described under "Experimental Procedures." Bax (A), Bcl2 (B) and BclXL (C) mRNA levels in liver were measured using real-time PCR. The relative expression of each mRNA compared with 18 S rRNA was calculated according to the equation ({Delta}Ct = Cttarget - Ct18 S rRNA. The relative amount of target mRNA in control (open bar) and cSN50 peptide-treated animals (solid bar) was expressed as 2-({Delta}{Delta}Ct), where {Delta}{Delta}Cttreatment = {Delta}Cttreatment - {Delta}Ct0 control. Error bars indicate the ± S.E. of the mean value in four mice that are represented by each data point. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups (Student's t test).

 
Time-dependent Changes in Markers for Microvascular Injury—In this model of LPS-induced liver apoptosis the DNA fragmentation is demonstrated by 6 h along with extensive hemorrhagic necrosis of the liver (see Fig. 1A). Hemorrhage reflects a break in the integrity of microvascular endothelium associated with the formation of intravascular platelet thrombi (Fig. 1B). The mechanism of microvascular injury remains unexplained.

To sequentially analyze this process, we monitored circulating platelets. The platelet count demonstrated that its normal range is maintained during the first 4 h after administration of LPS and D-Gal (Fig. 7). However, a precipitous drop in circulating platelets occurred between 4 and 6 h. In tandem with platelet count, we measured FDP in murine serum by the staphylococcal clumping test that detects this marker of intra-vascular coagulation (22). FDP level was significantly increased at 4 and 6 h. For comparison, PAI-1, which promotes vascular thrombosis in mice (35), was significantly increased at 6 h. The mice injected with LPS alone (n = 4) or D-Gal alone (n = 4) did not show alterations in platelet count. In contrast, PAI-1 levels were elevated in LPS-challenged mice but not in those that received D-Gal alone (data not shown). Thus, these markers of microvascular injury peak at 6 h when there is histologic evidence of massive apoptosis of the liver and wide-spread hemorrhagic necrosis in response to LPS and D-Gal (Fig. 1, A and B). More importantly, these markers of microvascular injury were significantly suppressed when mice were treated with the cSN50 peptide, further indicating the overall dependence of this process on the nuclear import of proinflammatory SRTFs.



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 7.
Time-dependent changes in the markers of microvascular injury in control and cSN50 peptide-treated mice. Wild-type C57BL/6 mice were treated with diluent (circles) or cSN50 peptide (triangles) as indicated in Fig. 3 before and after intraperitoneal administration of LPS with D-Gal. Platelet count (A) was performed manually, and FDP levels in serum were measured by the staphylococcal clumping test in which the clumping titer was expressed as a reciprocal of the highest dilution of tested serum giving a positive clumping reaction (B). PAI-1 total antigen (C) in plasma was measured by ELISA. Error bars indicate the ± S.E. of the mean value in four mice/group (A and B) or 9 mice/group (C) that are represented by each data point. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups (two-way ANOVA).

 
Massive Apoptosis of the Liver and Survival of the Mice Are Dependent on Nuclear Import of SRTFs—A combination of LPS and D-Gal in this model leads to death with massive apoptosis and hemorrhagic necrosis of the liver. As documented in Fig. 8, control mice treated with diluent showed characteristic progressive signs of sickness resulting in the early death of 26 of the 28 mice within 6–12 h. In contrast, the administration of the cSN50 peptide produced a dramatically protective effect. Twenty of 28 mice recovered fully from LPS/D-Gal challenge and survived at least 72 h. Thus, the cSN50 peptide increased survival from 7 to 71%. Based on the log rank test, the difference in the survival rate between cSN50 peptide-treated mice and the control mice was statistically significant (p < 0.0001). Another group of 15 mice, which were treated with the SM peptide (twice the cumulative dose level of cSN50), showed rapid signs of LPS/D-Gal toxicity and died within 6–12 h (results not shown). These control experiments with the SM peptide containing a mutated NLS confirm the essential role of this sequence in nuclear import blockade achieved with cSN50. Mice that received either LPS (1 µg) alone (n = 5) or D-Gal (20 mg) alone (n = 10) did not show signs of sickness and survived (data not shown). These survival data correlated with suppression of apoptotic injury and hemorrhagic necrosis of the liver (Fig. 8B). Non-survivors exhibited severe liver injury characterized by extensive apoptosis and hemorrhagic necrosis. In contrast, the mice that were treated with the cSN50 peptide and survived showed normal tissue architecture with normal content of periodic acid-Schiff-positive material (e.g. glycogen) and without signs of apoptosis. Thus, a nuclear import inhibitor in this model prevents the entire process of massive liver apoptosis and microvascular injury induced by LPS.



View larger version (62K):
[in this window]
[in a new window]
  		FIG. 8.
Survival and liver apoptosis accompanied by hemorrhagic necrosis in control mice as compared with the cSN50 peptide-treated mice. A, survival of wild-type C57BL/6 mice challenged with LPS and D-Gal that were treated with cSN50 peptide (triangles) or diluent (circles) as indicated in Fig. 3. p values represent the significance of the difference between the control and the cSN50 peptide-treated groups. B, liver sections stained with hematoxylin and eosin (H & E), periodic acid-Schiff (PAS), or with Apop Tag (TUNEL assay). Note the hallmarks of acute liver injury (apoptosis, hepatocyte necrosis, and erythrocyte extravasation) in diluent controls and preserved liver architecture without apoptosis and hemorrhagic necrosis in cSN50 peptide-treated mice. Histologic examination of survivors observed for 10 days showed no lesions (not shown). Mice receiving either D-Gal alone (n = 10) or LPS alone (n = 5) survived and after 3 days of observation showed no evidence of liver injury (not shown).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
This study demonstrated that blocking nuclear import of proinflammatory SRTFs counteracts a full-blown apoptosis and necrosis of the liver and has a death-sparing effect in this LPS-induced and macrophage-mediated model of fulminant liver failure. The SRTFs signaling network is an attractive target for therapeutic intervention in this context because a nuclear import inhibitor administered parenterally significantly offsets the hepatotoxicity of LPS. These new results expand the previous findings obtained in a different model of staphylococcal enterotoxin B-induced and T cell-based fatal liver injury (7). We have now demonstrated the beneficial effects of SRTF nuclear import blockade in two diverse models of liver injury. These highly reproducible models allow experimental study of an important biologic process. inflammation-associated apoptosis. Moreover, these models broaden our understanding of inflammation-driven liver apoptosis, which constitutes a life-threatening disease mechanism of increasing incidence. Among an estimated 2 billion cases of viral hepatitis worldwide, ~20 million will develop fulminant liver failure associated with apoptosis (6). Similarly, scores of alcoholic liver disease cases can be complicated by concomitant infection/inflammation-driven and TNF{alpha}-mediated apoptotic liver injury (36–38). The need for new therapeutic approaches to protect the liver from these devastating complications is apparent. Targeting nuclear import of proinflammatory SRTFs comprises one of the potential approaches to the control of inflammation-driven liver apoptosis.

The following lines of evidence establish the essential role of nuclear import of SRTFs in development of massive apoptosis and microvascular injury of the liver. (i) TNF{alpha}, a key inflammatory cytokine responsible for development of liver apoptosis (11, 24) was suppressed by our inhibitor of nuclear import of SRTFs, (ii) other inflammatory cytokines (IL-6 and IL-1{beta}) and the chemokine MCP-1 were also suppressed, indicating a broad spectrum of inhibition of these inflammatory mediators by cSN50 peptide in contrast to the inactive SM peptide containing mutated NLS, (iii) suppression of inflammatory mediators was accompanied by a cytoprotective effect on hepatocytes reflected by normal level of ALT and AST in serum of animals treated with cSN50, (iv) initiator and effector caspases were suppressed, and a balance between anti-apoptotic and pro-apoptotic gene transcripts was maintained, (v) DNA fragmentation in the liver cells was averted, (vi) microvascular injury was prevented, and (vii) survival of mice that were treated with cSN50, an inhibitor of SRTFs nuclear import, was significantly improved. In contrast to non-survivors that usually died within the first 12 h after administration of LPS and D-Gal, the surviving animals lived at least 3 days and did not display histologic evidence of liver injury. The lack of signs of liver and other organ injury in mice that received a nuclear import inhibitor persisted for at least a week when observation was extended. Thus, inhibition of nuclear import of SRTFs affords a lasting protection from highly deleterious effects of LPS and D-Gal that induce fulminant liver injury. The cSN50 peptide is rapidly (~20 min) distributed within mouse blood cells and organs after an intraperitoneal injection (18). However, further studies will be required to determine the pharmacokinetics, long-term toxicity, and therapeutic efficacy of this new class of nuclear import peptide inhibitors.

As depicted in Fig. 9, sequential analysis of the events leading to death due to LPS-induced fulminant liver injury indicates a lag phase of at least 4 h before activation of initiator and effector caspases was detected in the liver. During this lag phase the production and action of TNF{alpha} and other mediators of inflammation depend on signaling to the nucleus in LPS-responsive cells that encompass liver macrophages (Kupffer cells) (25). This LPS-induced signaling depends on expression of TLR4 because TLR4-deficient C3H/HeJ mice escape massive apoptosis (24). Moreover, there is a requirement for metabolic changes; without the depleting action of D-Gal on UTP in hepatocytes, LPS is unable to induce massive apoptosis despite a robust burst in TNF{alpha} (18). When administered alone, LPS is responsible for a rise in TNF{alpha} and other cytokines. Neither LPS nor D-Gal administered alone induces massive apoptosis of the liver and death (10). Thus, development of fulminant apoptosis requires a combination of transient hepatocyte metabolic dysfunction and the burst of inflammatory cytokines to overcome anti-apoptotic defenses of the liver.



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 9.
Schematic depiction of time course of cytokine/chemokine activation, hepatocyte injury as indicated by release of liver enzymes, apoptosis, and death in this model of LPS-induced liver injury. Abnormality index represents the -fold increase in parameter studied.

 
The experimental model employed in this study depends upon cross-talk between macrophages and hepatocytes as schematically depicted in Fig. 10. Macrophages respond to LPS via TLR-4 and produce TNF{alpha} along with other mediators of inflammation in a SRTFs nuclear import-dependent manner. Apparently, TNF{alpha} via its "death" receptor (TNFR-1) evokes a different pro-apoptotic signaling in a hepatocyte that is metabolically altered by D-Gal. The primary effect of D-Gal is its capacity to lower the level of UTP in hepatocytes (10, 24). A cascade of initiator and effector caspases is activated in hepatocytes and ultimately leads to the execution of a program of DNA fragmentation and chromatin condensation. Sequential analysis of pro-apoptotic and anti-apoptotic genes expression in the liver indicates that in this model of fulminant liver injury there is an early block in transcription of anti-apoptotic genes, Bcl2 and BclXL, before pro-apoptotic gene Bax is transcriptionally activated (Fig. 6). The Bax expression between 4 and 6 h coincided with activation of initiator caspases 8 and 9 (Fig. 7). Activation of caspase 8 reflects signaling by death receptors represented by TNFR-1. Activation of caspase 9 indicates that changes in mitochondrial integrity have occurred. Such changes are usually due to a rise in intracellular Ca2+, generation of reactive oxygen species, ceramide, and pro-apoptotic protein Bax (39, 40). These changes destabilize mitochondria and lead to the release of cytochrome c. Although we detected occasional DNA fragmentation in the liver using a TUNEL assay at 4 h, the most dramatic changes were observed at 6 h (Fig. 1A). Thus, pro-apoptotic signaling induced by TNF{alpha} in D-Gal-sensitized liver cells requires at least 4 h to overcome anti-apoptotic mechanisms as documented in Fig. 1. Subsequently, sometime between the fourth and sixth hour, the consequences of the "life or death" decision made by hepatocytes become apparent. Thus, this 2-h time span is decisive for development of a full-blown apoptosis. Importantly, overexpression of Bcl2 prevents cells from undergoing apoptosis by blocking cytochrome c release from mitochondria induced by a variety of stimuli (41). Moreover, inhibition of caspase-3 activity with YVAD-chloromethyl ketone protected mice from liver apoptosis and death caused by LPS and D-Gal (42).



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 10.
Diagrammatic representation of the cross talk of macrophages and hepatocytes during LPS-induced liver apoptosis. LPS interaction with Toll-like receptor 4 (TLR-4), which is associated with CD14, evokes in macrophages a cascade of signaling events leading to nuclear import of SRTF. As a consequence, genes that encode inflammatory cytokines and chemokine are activated (Figs. 2 and 3). Expressed TNF{alpha} interacts with its cognate death receptor TNFR-1, which triggers a cascade of initiator and executioner caspases in D-Gal-sensitized hepatocytes, which have a depleted supply of UTP (Fig. 5). The DNA fragmentation ensues. The cSN50 peptide blocks the nuclear import of SRTFs and prevents the activation of genes that encode inflammatory cytokines/chemokines and PAI-1. See "Discussion" for details. FADD, FAS (TNFRSF6)-associated death domain protein. TRADD, TNFRSF1A-associated via death domain. TRAF, TNF receptor-associated factor. tBid, truncated BH3-interacting domain death agonist. RIP, receptor (TNFRSF)-interacting serine-threonine kinase 1.

 
The association of massive apoptosis of the liver with hemorrhagic necrosis reflects a concomitant microvascular injury due to a loss of endothelial integrity with attendant extravasation of erythrocytes and intravascular formation of platelet aggregates (Fig. 1B). This is accompanied by a precipitous decrease in circulating platelets and generation of FDP. In view of the fulminant nature of liver failure in this model, our inability to detect fibrin in histologic sections is not surprising. Nevertheless, combination of acute platelet consumption and generation of FDP strongly suggests a process of microvascular injury with thrombosis (43). Consistent with this process, increased expression of PAI-1 was detected. The cSN50 peptide prevented all of these abnormal changes. Thus, three interwoven mechanisms, inflammation, apoptosis, and microvascular dysfunction, depend on induction of a genetic program regulated by SRTFs and controlled by their nuclear import.

Broad inhibition of inducible SRTFs nuclear import prevents massive apoptosis of the adult liver, whereas disruption of physiologic signaling mediated by NF{kappa}B led to TNF{alpha}-dependent apoptosis of fetal liver (44–46). Although the cSN50 peptide inhibits nuclear import of NF{kappa}B, it also blocks nuclear translocation of activator protein 1, nuclear factor of activated T cells, and signal transducer and activator of transcription 1 (17, 18). Apparently, the coordinated regulation of genes that encode mediators of inflammation and apoptosis by multiple SRTFs exceeds the unique role of NF{kappa}B in protecting fetal liver from TNF{alpha}-mediated developmental injury.

Taken together, our experiments identify a key rate-limiting step in the development of LPS-induced apoptosis of the liver that may be amenable to therapeutic intervention with nuclear import inhibitors. TNF{alpha} production and subsequent hepatocyte apoptosis may contribute to the development of a number of inflammatory liver diseases, including viral hepatitis, alcoholic liver disease, Wilson disease, drug-induced liver failure, and ischemia/reperfusion liver damage (34, 47, 48). Moreover, our results may have therapeutic applications for other disease conditions, such as secondary organ injury after ischemia/reperfusion, due to the excessive production of inflammatory cytokines and subsequent neutrophil involvement (49). Thus, targeting nuclear import of proinflammatory SRTFs offers a new approach to suppress expression of inflammatory and apoptotic mediators in the liver and interrupt the underlying disease mechanisms.


   FOOTNOTES
 
* This work was supported in part by United States Public Health Service, National Institutes of Health Grants HL69542, HL62356, HL68744, and DK54072. The use of core facilities in this study was supported by National Institutes of Health Grants 2P30 CA 68485 (to the Vanderbilt Ingram Cancer Center) and 5P30DK058404-03 (to the Vanderbilt Digestive Disease Research Center). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Vanderbilt University School of Medicine, 1161 21st Ave. South, A-5321 MCN, Nashville, TN 37232-2363. Tel.: 615-343-8280; Fax: 615-343-8278; E-mail: jacek.hawiger{at}vanderbilt.edu.

1 The abbreviations used are: D-Gal, 2-amino-2-deoxy-D-galactosamine; TLR, Toll-like receptors; LPS, lipopolysaccharide; TNF{alpha}, tumor necrosis factor {alpha}; TNFR-1, tumor necrosis factor {alpha} receptor 1; SRTF, stress-responsive transcription factors; NF{kappa}B, nuclear factor {kappa}B; cSN50, cyclized form of SN50 peptide carrying an NLS derived from NF{kappa}B1 (p50); SM, control peptide carrying a non-functional NLS mutation; RAW, murine macrophage cell line RAW 264.7; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FDP, fibrin degradation products; PAI-1, plasminogen activator inhibitor-1; TUNEL, TdT-dependent dUTP-biotin nick end labeling; ANOVA, analysis of variance; NLS, nuclear localization sequence. Back


   ACKNOWLEDGMENTS
 
We thank Dean Ballard for critical reading of the manuscript, Ruth Ann Veach for experimental advice, and Hui Cai for help with statistical analyses. We also thank Ana Maria Hernandez for assistance in the preparation of the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Danial, N. N., and Korsmeyer, S. J. (2004) Cell 116, 205-219[CrossRef][Medline] [Order article via Infotrieve]
  2. Jaeschke, H., Gujral, J. S., and Bajt, M. L. (2004) Liver Int. 24, 85-89[CrossRef][Medline] [Order article via Infotrieve]
  3. Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G. P., Nunes, F., Haskal, Z. J., Furth, E. E., Propert, K. J., Robinson, M. B., Magosin, S., Simoes, H., Speicher, L., Hughes, J., Tazelaar, J., Wivel, N. A., Wilson, J. M., and Batshaw, M. L. (2002) Hum. Gene Ther. 13, 163-175[CrossRef][Medline] [Order article via Infotrieve]
  4. Doerschug, K., Sanlioglu, S., Flaherty, D. M., Wilson, R. L., Yarovinsky, T., Monick, M. M., Engelhardt, J. F., and Hunninghake, G. W. (2002) J. Immunol. 169, 6539-6545[Abstract/Free Full Text]
  5. Shayakhmetov, D. M., Li, Z. Y., Ni, S., and Lieber, A. (2004) J. Virol. 78, 5368-5381[Abstract/Free Full Text]
  6. Matsumoto, G., Tsunematsu, S., Tsukinoki, K., Ohmi, Y., Iwamiya, M., Oliveira-dos-Santos, A., Tone, D., Shindo, J., and Penninger, J. M. (2002) J. Immunol. 169, 7087-7096[Abstract/Free Full Text]
  7. Liu, D., Liu, X. Y., Robinson, D., Burnett, C., Jackson, C., Seele, L., Veach, R. A., Downs, S., Collins, R. D., Ballard, D. W., and Hawiger, J. (2004) J. Biol. Chem. 279, 19239-19246[Abstract/Free Full Text]
  8. Miethke, T., Wahl, C., Heeg, K., Echtenacher, B., Krammer, P. H., and Wagner, H. (1992) J. Exp. Med. 175, 91-98[Abstract/Free Full Text]
  9. Deaciuc, I. V., Nikolova-Karakashian, M., Fortunato, F., Lee, E. Y., Hill, D. B., and McClain, C. J. (2000) Alcohol Clin. Exp. Res. 24, 1557-1565[CrossRef][Medline] [Order article via Infotrieve]
  10. Galanos, C., Freudenberg, M. A., and Reutter, W. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5939-5943[Abstract/Free Full Text]
  11. Morikawa, A., Sugiyama, T., Kato, Y., Koide, N., Jiang, G. Z., Takahashi, K., Tamada, Y., and Yokochi, T. (1996) Infect. Immun. 64, 734-738[Abstract]
  12. Car, B. D., Eng, V. M., Schnyder, B., Ozmen, L., Huang, S., Gallay, P., Heumann, D., Aguet, M., and Ryffel, B. (1994) J. Exp. Med. 179, 1437-1444[Abstract/Free Full Text]
  13. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., and Bluethmann, H. (1993) Nature 364, 798-802[CrossRef][Medline] [Order article via Infotrieve]
  14. Pfeffer, K., Matsuyama, T., Kundig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Kronke, M., and Mak, T. W. (1993) Cell 73, 457-467[CrossRef][Medline] [Order article via Infotrieve]
  15. Hawiger, J. (2001) Immunol. Res. 23, 99-109[CrossRef][Medline] [Order article via Infotrieve]
  16. Weis, K. (2003) Cell 112, 441-451[CrossRef][Medline] [Order article via Infotrieve]
  17. Torgerson, T. R., Colosia, A. D., Donahue, J. P., Lin, Y. Z., and Hawiger, J. (1998) J. Immunol. 161, 6084-6092[Abstract/Free Full Text]
  18. Liu, X. Y., Robinson, D., Veach, R. A., Liu, D., Timmons, S., Collins, R. D., and Hawiger, J. (2000) J. Biol. Chem. 275, 16774-16778[Abstract/Free Full Text]
  19. Chen, R., Lowe, L., Wilson, J. D., Crowther, E., Tzeggai, K., Bishop, J. E., and Varro, R. (1999) Clin. Chem. 45, 1693-1694[Free Full Text]
  20. Gibson, U. E., Heid, C. A., and Williams, P. M. (1996) Genome Res. 6, 995-1001[Abstract/Free Full Text]
  21. Yajima, T., Yagihashi, A., Kameshima, H., Kobayashi, D., Furuya, D., Hirata, K., and Watanabe, N. (1998) Clin. Chem. 44, 2441-2445[Abstract/Free Full Text]
  22. Hawiger, J., Niewiarowski, S., Gurewich, V., and Thomas, D. P. (1970) J. Lab. Clin. Med. 75, 93-108[Medline] [Order article via Infotrieve]
  23. Freudenberg, M. A., Keppler, D., and Galanos, C. (1986) Infect. Immun. 51, 891-895[Abstract/Free Full Text]
  24. Lehmann, V., Freudenberg, M. A., and Galanos, C. (1987) J. Exp. Med. 165, 657-663[Abstract/Free Full Text]
  25. Song, Y., Shi, Y., Ao, L. H., Harken, A. H., and Meng, X. Z. (2003) World J. Gastroenterol. 9, 1799-1803[Medline] [Order article via Infotrieve]
  26. Feng, J. M., Shi, J. Q., and Liu, Y. S. (2003) Hepatobiliary Pancreat. Dis. Int. 2, 265-269[Medline] [Order article via Infotrieve]
  27. Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., and Seeff, L. B. (2000) Clin. Chem. 46, 2027-2049[Abstract/Free Full Text]
  28. Green, D., and Kroemer, G. (1998) Trends Cell Biol. 8, 267-271[CrossRef][Medline] [Order article via Infotrieve]
  29. Wang, X. (2001) Genes Dev. 15, 2922-2933[Free Full Text]
  30. Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997) Cell 89, 175-184[CrossRef][Medline] [Order article via Infotrieve]
  31. Liu, X., Li, P., Widlak, P., Zou, H., Luo, X., Garrard, W. T., and Wang, X. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8461-8466[Abstract/Free Full Text]
  32. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) Nature 391, 43-50[CrossRef][Medline] [Order article via Infotrieve]
  33. Adams, J. M., and Cory, S. (1998) Science 281, 1322-1326[Abstract/Free Full Text]
  34. Yin, X. M., and Ding, W. X. (2003) Curr. Mol. Med. 3, 491-508[CrossRef][Medline] [Order article via Infotrieve]
  35. Eitzman, D. T., Westrick, R. J., Nabel, E. G., and Ginsburg, D. (2000) Blood 95, 577-580[Abstract/Free Full Text]
  36. Zhou, Z., Wang, L., Song, Z., Lambert, J. C., McClain, C. J., and Kang, Y. J. (2003) Am. J. Pathol. 163, 1137-1146[Abstract/Free Full Text]
  37. McMullen, M. R., Cocuzzi, E., Hatzoglou, M., and Nagy, L. E. (2003) J. Biol. Chem. 278, 38333-38341[Abstract/Free Full Text]
  38. Lieber, C. S. (1988) N. Engl. J. Med. 319, 1639-1650[Medline] [Order article via Infotrieve]
  39. Kadenbach, B., Arnold, S., Lee, I., and Huttemann, M. (2004) Biochim. Bio-phys. Acta 1655, 400-408[Medline] [Order article via Infotrieve]
  40. Osawa, Y., Banno, Y., Nagaki, M., Nozawa, Y., Moriwaki, H., and Nakashima, S. (2001) Liver 21, 309-319[CrossRef][Medline] [Order article via Infotrieve]
  41. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., and Wang, X. (1997) Science 275, 1129-1132[Abstract/Free Full Text]
  42. Mignon, A., Rouquet, N., Fabre, M., Martin, S., Pages, J. C., Dhainaut, J. F., Kahn, A., Briand, P., and Joulin, V. (1999) Am. J. Respir. Crit. Care Med. 159, 1308-1315[Abstract/Free Full Text]
  43. Wada, H., Gabazza, E. C., Asakura, H., Koike, K., Okamoto, K., Maruyama, I., Shiku, H., and Nobori, T. (2003) Am. J. Hematol. 74, 17-22[CrossRef][Medline] [Order article via Infotrieve]
  44. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve]
  45. Doi, T. S., Marino, M. W., Takahashi, T., Yoshida, T., Sakakura, T., Old, L. J., and Obata, Y. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2994-2999[Abstract/Free Full Text]
  46. Rosenfeld, M. E., Prichard, L., Shiojiri, N., and Fausto, N. (2000) Am. J. Pathol. 156, 997-1007[Abstract/Free Full Text]
  47. Oreopoulos, G. D., Wu, H., Szaszi, K., Fan, J., Marshall, J. C., Khadaroo, R. G., He, R., Kapus, A., and Rotstein, O. D. (2004) Hepatology 40, 211-220[CrossRef][Medline] [Order article via Infotrieve]
  48. McCarter, S. D., Akyea, T. G., Lu, X., Bihari, A., Scott, J. R., Badhwar, A., Dungey, A. A., Harris, K. A., Feng, Q., and Potter, R. F. (2004) Surgery 136, 67-75[CrossRef][Medline] [Order article via Infotrieve]
  49. Qiu, F. H., Wada, K., Stahl, G. L., and Serhan, C. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4267-4272[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
K. Kumagai, K. Ito, Y. Ando, S. Hakamata, M. Teranishi, H. Nakayama, and S. Manabe
Neutralization of IL-10 Exacerbates Cycloheximide-Induced Hepatocellular Apoptosis and Necrosis
Toxicol Pathol, June 1, 2009; 37(4): 536 - 546.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-I. Kim, J.-E. Park, A. Martinez-Hernandez, and A.-K. Yi
CpG DNA Prevents Liver Injury and Shock-mediated Death by Modulating Expression of Interleukin-1 Receptor-associated Kinases
J. Biol. Chem., May 30, 2008; 283(22): 15258 - 15270.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Le Minh, K. Klemm, K. Abshagen, C. Eipel, M. D. Menger, and B. Vollmar
Attenuation of Inflammation and Apoptosis by Pre- and Posttreatment of Darbepoetin-{alpha} in Acute Liver Failure of Mice
Am. J. Pathol., June 1, 2007; 170(6): 1954 - 1963.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. A. Samuel, J. D. Morrey, and M. S. Diamond
Caspase 3-Dependent Cell Death of Neurons Contributes to the Pathogenesis of West Nile Virus Encephalitis
J. Virol., March 15, 2007; 81(6): 2614 - 2623.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L Frelin, E D Brenndorfer, G Ahlen, M Weiland, C Hultgren, M Alheim, H Glaumann, B Rozell, D R Milich, J G Bode, et al.
The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor {alpha} mediated liver disease
Gut, October 1, 2006; 55(10): 1475 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A.-K. Yi, H. Yoon, J.-E. Park, B.-S. Kim, H. J. Kim, and A. Martinez-Hernandez
CpG DNA-mediated Induction of Acute Liver Injury in D-Galactosamine-sensitized Mice: THE MITOCHONDRIAL APOPTOTIC PATHWAY-DEPENDENT DEATH OF HEPATOCYTES
J. Biol. Chem., May 26, 2006; 281(21): 15001 - 15012.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Tsuruma, T. Nakagawa, N. Morimoto, M. Minami, H. Hara, T. Uehara, and Y. Nomura
Glucocorticoid Modulatory Element-binding Protein 1 Binds to Initiator Procaspases and Inhibits Ischemia-induced Apoptosis and Neuronal Injury
J. Biol. Chem., April 21, 2006; 281(16): 11397 - 11404.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. J. Arinze and Y. Kawai
Transcriptional Activation of the Human G{alpha}i2 Gene Promoter through Nuclear Factor-{kappa}B and Antioxidant Response Elements
J. Biol. Chem., March 18, 2005; 280(11): 9786 - 9795.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/46/48434    most recent
M407190200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, D.
Right arrow Articles by Hawiger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, D.
Right arrow Articles by Hawiger, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement